Announcements Trials
Browse Landscape

Phase

Phase 2 55Phase 1 29Phase 3 6Phase 1/2 6Phase 2/3 4Phase NA 2Phase EARLY_PHASE1 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 1Inflammatory Breast Neoplasms 1Breast Neoplasms 1

Interventions

Exercise 439Blood Specimen Collection 333Standard of Care 321Magnetic Resonance Spectroscopy 259Radiotherapy 255Surveys and Questionnaires 245Radiosurgery 245Educational Status 230Methods 229Early Intervention, Educational 218Practice Guidelines as Topic 146Interviews as Topic 146Biopsy 146Surgical Procedures, Operative 135Drug Therapy 133Control Groups 128Acupuncture Therapy 124Therapeutics 110Cyclophosphamide 103Palliative Care 101Counseling 101Resistance Training 95Saline Solution 90Cisplatin 90Magnetic Resonance Imaging 89Radiofrequency Ablation 86Specimen Handling 79Radiotherapy, Intensity-Modulated 79Colonoscopy 79Cognitive Behavioral Therapy 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × cediranib × Clear all
NCT02681237 2022-05-09

A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer

University Health Network, Toronto

Phase NA Completed
34 enrolled
Gynecologic

Ovarian Neoplasms

NCT00310089 2013-06-20

AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer

National Cancer Institute (NCI)

Phase NA Completed
33 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡